CAC
NBIX icon

Cowen and Company’s Neurocrine Biosciences NBIX Stock Holding History

Cowen and Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,500
Closed -$77K – 656
2021
Q1 		$77K Sell
6,500
-6,000
-48% -$629K 0.01% 345
2020
Q4 		$42K Buy
+12,500
New +$1.21M ﹤0.01% 289

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cowen and Company's NBIX Position: Q1 2024 in Review

Cowen and Company sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 18,668 shares — an estimated $2.46M sold.

Cowen and Company first reported a position in NBIX in Q1 2021 and held it in 2 quarters. The position peaked at $2.46M in Q4 2023. 590 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Cowen and Company reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 18,668 Neurocrine Biosciences shares in Q1 2024, an estimated $2.46M.
  • Cowen and Company first reported a position in Neurocrine Biosciences in Q1 2021 and held it in 2 quarters.
  • Cowen and Company's Neurocrine Biosciences position peaked at $2.46M in Q4 2023.
  • 590 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.